Please login to the form below

Not currently logged in

Chiesi's Holoclar wins UK Prix Galien orphan drug award

Novartis and Astellas also scoop prizes at the prestigious ceremony

Prix Galien Chiesi Holoclar 

A ground-breaking stem cell treatment for a rare eye condition that can lead to blindness was rewarded with the 2016 Prix Galien's Orphan Product Award earlier this week in London.

Chiesi's Holoclar was the first stem cell treatment to be approved in Europe when it was licensed in 2015 to treat moderate-to-severe forms of limbal stem cell deficiency (LSCD).

Professor Sir Michael Rawlins, chair of the UK Prix Galien judges, said: “LSCD may affect one or both eyes; left untreated it results in chronic pain, photophobia, inflammation, corneal neovascularisation and the reduction or complete loss of vision. 

“Holoclar consists of a sheet of viable autologous human corneal epithelial cells and is transplanted into the affected eye(s) after removal of the damaged corneal epithelium. The Judging Panel agreed that it was tremendous to see this level of innovation in an orphan indication.”

Chiesi's UK managing director Tom Delahoyde said: “Chiesi is extremely pleased that Holoclar has been recognised as an innovative orphan product by such a prestigious award. 

“[The award] recognises the hard work that has gone into researching and developing this exciting product, and ensuring that a high need patient group has access to innovative treatment options.”

Also rewarded at the bi-annual ceremony were Novartis with the Innovative Product Award and Astellas with The Real World Evidence Award.

Novartis' Entresto caught the judges' attention as the first new treatment for heart failure in 15 years, and one that offers a unique approach to the treatment.

It marks the fourth UK Prix Galien for the company since 2002 and its second successive Innovative Product Award, after winning the category in 2014 with Bexsero.

Meanwhile, the inaugural Real World Data Award went to Astellas for its first-in-class antibiotic Dificlir

Specifically the judges were impressed by a unique series of local service evaluations on its NHS impact conducted in 2013-14. “Results indicated the very significant contribution that Dificlir's use can make to tackling the major public health problems of antimicrobial resistance through targeted antibiotic therapy and infection control,” said Professor Sir Michael.

Commenting on the results as a whole Karen Westaway, chief executive of ValueBase, the new owners of Prix Galien's UK franchise, said: “UK Prix Galien has once again showed the depth and diversity of medical innovation in UK life sciences.

“In an Olympic year, it's easy to see why UK pharma consistently remains at the top of the global medal table for innovation.”

Article by
Dominic Tyer

23rd September 2016

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....